Open-label, Single-dose Studies of the Pharmacokinetics of Edaravone in Subjects with Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects with Normal Hepatic Functioning - Nakamaru, Yoshinobu; Kakubari, Masae; Yoshida, Kaori; Akimoto, Makoto; Todorovic, Vesna; Greis, Thomas; Kondo, Kazuoki (Clinical therapeutics, 2020)
Keywords: Adolescent; Adult; Aged; Amyotrophic lateral sclerosis; Area Under Curve; Birth control; Body mass index; Bradycardia; Bradycardia - chemically induced; Cytochrome; Disease; Dosage; Drug dosages; edaravone; Edaravone - adverse effects; Edaravone - blood; Edaravone - pharmacokinetics; FDA approval; Female; Free Radical Scavengers - adverse effects; Free Radical Scavengers - blood; Free Radical Scavengers - pharmacokinetics; hepatic insufficiency; Humans; Internal Medicine; Liver; Liver Diseases - blood; Liver Diseases - metabolism; Male; Medical Education; Medical laboratories; Metabolites; Middle Aged; mild–moderate; Neuroprotective Agents - adverse effects; Neuroprotective Agents - blood; Neuroprotective Agents - pharmacokinetics; Pharmacokinetics; severe; Sulfates; tolerability; Urine; Vital signs; Young Adult; Japan; hepatic insufficiency; pharmacokinetics; mild–moderate; edaravone; severe; tolerability